Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 14.35M | 9.60M | 7.21M | 2.50M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.35M | 9.60M | 7.21M | 2.50M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 14.35M | 9.60M | 7.21M | 2.50M | -- |
| SG&A Expenses | 29.97M | 30.06M | 33.94M | 36.66M | 41.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.23M | 92.30M | 99.90M | 128.28M | 158.21M |
| Operating Income | -72.88M | -82.70M | -92.69M | -125.78M | -158.21M |
| Income Before Tax | -215.03M | -124.47M | -133.96M | -166.66M | -161.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -215.03 | -124.47 | -133.96 | -166.66 | -161.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -215.03M | -124.47M | -133.96M | -166.66M | -161.32M |
| EBIT | -72.88M | -82.70M | -92.69M | -125.78M | -158.21M |
| EBITDA | -71.51M | -81.39M | -91.44M | -124.61M | -157.19M |
| EPS Basic | -2.58 | -2.30 | -2.76 | -3.80 | -4.14 |
| Normalized Basic EPS | -1.19 | -1.02 | -1.31 | -1.96 | -2.59 |
| EPS Diluted | -2.58 | -2.30 | -2.76 | -3.80 | -4.14 |
| Normalized Diluted EPS | -1.19 | -1.02 | -1.31 | -1.96 | -2.59 |
| Average Basic Shares Outstanding | 309.59M | 224.83M | 200.73M | 175.64M | 157.37M |
| Average Diluted Shares Outstanding | 309.59M | 224.83M | 200.73M | 175.64M | 157.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |